ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

ASX 200 healthcare shares vastly outperformed their peers, rising 9.21%, as earnings season continued last week.

Pleasing FY26 reports from heavyweights CSL Ltd (ASX: CSL) and Pro Medicus Ltd (ASX: PME) turbocharged the sector.

The broader S&P/ASX 200 Index (ASX: XJO) slipped 0.62% over the week to 9,058.9 points on Friday.

Healthcare is in the middle of a rapid recovery following a 29% slump over the 12 months to early June.

The S&P/ASX 200 Health Care Index (ASX: XHJ) reached a 9-year low on 3 June.

The sector then pivoted as value investors rushed in to snap up blue-chips on the cheap.

Healthcare shares have skyrocketed 41% since 3 June, compared to a 3% rise for the ASX 200.

Let’s review some specifics from last week.

Healthcare shares led the ASX sectors last week

Last week, several major healthcare companies revealed their latest periodic earnings results.

The CSL share price leapt 23.3% to $168.30 on the strength of its FY26 results last week.

CSL shares have rocketed 82% since the healthcare sector rebound began on 3 June.  

Pro Medicus shares jumped 7.1% to $191.60 on the back of the company’s FY26 report.

The Pro Medicus share price is up 20% since 3 June. 

The Cochlear Ltd (ASX: COH) share price rose 1.4% to $135.48 following the hearing implant maker’s FY26 report.

Cochlear shares have increased 42% since 3 June.

The Healius Ltd (ASX: HLS) share price jumped 13.8% to 46 cents following its FY26 report last week.

Healius shares are up 38% since 3 June.

The EBOS Group Ltd (ASX: EBO) share price ascended 7.2% to $18.96 following the company’s FY26 results.

EBOS shares are up 20% since 3 June.

The Mesoblast Ltd (ASX: MSB) share price lifted 6.8% to $2.36 following a phase 3 trial update.

Mesoblast shares have risen 17% since 3 June.  

ASX 200 market sector snapshot

Here’s how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days: